// App-Quantinova.ai

7512 : Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

Researchers

Presenter

  • Catherine S. Magid Diefenbach

Principal Investigators

  • Pau Abrisqueta

  • Eva Gonzalez-Barca

  • Carlos Panizo

  • Jose Maria Arguinano Perez

  • Fiona Miall

  • Mariana Bastos-Oreiro

  • Armando Lopez-Guillermo

  • Lalita Banerjee

  • Andrew McMillan

  • Jamie Hirata

  • Lisa Musick

  • Sourish Saha

  • Brandon Croft

  • Erlene Kuizon Seymour

Medical Centers

  • Perlmutter Cancer Center NYU Langone, New York, NY

  • University Hospital Vall d'Hebron, Barcelona, Spain

  • Instititut Catala D'Oncologia, IDIBELL, Universitat de Barcelona, Barcelona, Spain

  • University Clinic of Navarra and Healthcare Research Institute of Navarra (IdiSNA), Pamplona, Spain

  • Complejo Hospitalario de Navarra, Pamplona, Spain

  • Department of Rheumatology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

  • Hospital Universitario Quiron Madrid, Madrid, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Rheumatology, Maidstone and Tunbridge Wells Hospital, Kent, United Kingdom

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

Locations

  • United States

  • Spain

  • United Kingdom

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Polatuzumab vedotin

  • Lenalidomide

  • Rituximab

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02600897

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved